FY2025 EPS Estimates for Rallybio Lifted by HC Wainwright

Rallybio Co. (NASDAQ:RLYB) – Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Rallybio in a report released on Monday, March 17th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.20) per share for the year, up from their prior forecast of ($1.22). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, March 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million.

Rallybio Price Performance

Shares of NASDAQ:RLYB opened at $0.73 on Wednesday. The firm has a market capitalization of $30.47 million, a PE ratio of -0.46 and a beta of -1.45. The business has a 50-day moving average of $0.80 and a two-hundred day moving average of $0.97. Rallybio has a 12 month low of $0.62 and a 12 month high of $3.46.

Institutional Investors Weigh In On Rallybio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northeast Financial Consultants Inc increased its stake in Rallybio by 336.5% during the fourth quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after acquiring an additional 74,334 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Rallybio by 11.4% in the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock worth $287,000 after buying an additional 24,980 shares during the period. Renaissance Technologies LLC boosted its position in shares of Rallybio by 9.3% in the fourth quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after buying an additional 37,618 shares during the period. Allostery Investments LP purchased a new stake in shares of Rallybio in the fourth quarter worth about $771,000. Finally, Almitas Capital LLC boosted its position in shares of Rallybio by 48.3% in the fourth quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock worth $1,246,000 after buying an additional 422,685 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.